Expression of cellular and inflammatory factors in tumorigenic HBEC clones inducibly expressing PPARγ

<p>(A) Immunoblots using antibodies against PPARγ, cyclin A, cyclin D1, p16, or beta-actin were used to measure the corresponding protein expression in tumorigenic HBECs expressing wt-PPARγ or SUMO-PPARγ when treated with 3 μM of TZDs. (B) COX2 (left) and 15-PGDH (right) expression upon activation of wt-PPARγ or SUMO-PPARγ with 3 μM of TZD treatments. The expression of COX2 protein was measured by immunoblot assay in HBEC-C1 cell lines, HBEC-C1-wt-PPARγ and HBEC-C1-SUMO-PPARγ, treated with 3 μM of TZDs (e.g., pioglitazone or troglitazone) under tet-ON or -OFF condition. The relative level of COX2 expression was referenced by the corresponding beta-actin level and further normalized by the vehicle-treated sample in each group (left-bottom in B). 15-PGDH mRNA expression was measured using QPCR assay in the same sample sets (right panel in B). Data represent the mean ± SD (n = 3). Asterisks show statistically significant points as evaluated by <i>ANOVA</i>. *<i>P</i> < 0.001 compared to HBEC-KT control.